Viron Therapeutics Inc.
Viron Therapeutics Inc. is a clinical stage drug development company with a leading position in the treatment of inflammatory disorders. Viron is a pioneer in exploiting natural viral proteins as innovative drugs for the treatment of human disorders resulting from abnormal inflammatory responses, such as cardiovascular disease, transplant vasculopathy and rheumatoid arthritis. The company’s lead compound, VT-111, recently entered a Phase 2 clinical trial in patients with Acute Coronary Syndromes (ACS) and is also undergoing late preclinical studies for the treatment of transplant vaculopathy. Viron’s additional pipeline of 5 compounds in preclinical development combined with a robust discovery program, strongly position the company to become a leader in the treatment of inflammatory disorders. Viron was recently honoured as the 2005 recipient of the prestigious Prix Galien Canada Award in Biotechnology, one of the highest honours in the pharmaceutical and biotechnology industry.
contact: Kevin Sullivan, Manager Business Development 519.858.5109
website: www.vironinc.com